DPP-4 Inhibitors | diabetes
Links shared publicly online about this topic.
- 188total visits
DPP-4 Inhibitors | diabetes
View full resource at diabeticlive.com
Tags: Diabetes, Blood Sugar, Insulin, Type 2 Diabetes, Drug
Most Recently Shared on June 27, 2011 at 1:53 pm By:
Aliskiren-containing Medications: Drug Safety Comunication - New Warning and Contraindication
fda.gov — “Risk of renal impairment, hypotension, and hyperkalemia with concomitant use of aliskiren with angiotensin receptor blockers (ARBs) or angiotensin converting enzyme inhibitors (ACEIs) in patients with diabetes.” View full resource at fda.gov
Most Recently Shared on April 20, 2012 at 4:08 pm By:
#Safety ALERT: #Aliskiren-containing Meds: #pharm #endo #med #APRN - New Warning & Contraindication: http://t.co/0AgfKNXf
Idera commences IMO-3100 Phase 2 clinical trial for psoriasis
news-medical.net — “Idera Pharmaceuticals, Inc. today announced the treatment of the first patient in a Phase 2 clinical trial of IMO-3100, the Company's lead Toll-like receptor (TLR) inhibitor for the treatment of autoimmune diseases, in patients with moderate to severe plaque psoriasis.” View full resource at news-medical.net
Most Recently Shared on April 18, 2012 at 6:26 am By:
Idera commences IMO-3100 Phase 2 clinical trial for psoriasis: Idera Pharmaceuticals, Inc. today announced the t... http://t.co/wEfJcG0T
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin
annals.org — “Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin” View full resource at annals.org
Most Recently Shared on March 20, 2012 at 6:05 pm By:
Ves Dimov, M.D. Internist, Allergist, Physician, and Doctor
Dapagliflozin, selective inhibitor of sodium–glucose cotransporter 2, improves glycemic control in DM2 http://t.co/sP93HAyu
Dipeptidyl peptidase-4 inhibitors for treatment of type ... [BMJ. 2012] - PubMed - NCBI
ncbi.nlm.nih.gov — “PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on March 16, 2012 at 8:11 pm By:
Tom Heston, MD Doctor, Family Medicine Doctor, and Physician
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clini... http://t.co/xlDSlrNK #medicine
Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence
clinical.diabetesjournals.org — “Choosing GLP-1 Receptor Agonists or DPP-4 Inhibitors: Weighing the Clinical Trial Evidence” View full resource at clinical.diabetesjournals.org
Most Recently Shared on February 4, 2012 at 4:21 am By:
Yvo Sijpkens MD Nephrologist, Physician, Doctor, and Internist
How to select among GLP-1 receptor agonists and DPP-4 inhibitors? #diabetes http://t.co/4PpobaSG
Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes
news-medical.net — “Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.” View full resource at news-medical.net
Most Recently Shared on January 31, 2012 at 12:29 pm By:
Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes: Boehringer Ingelheim P... http://t.co/QrEPkXXO
FDA Advises Caution When IV Methotrexate-PPI Used Together : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on December 21, 2011 at 7:33 pm By:
Bob Finn - Medical News Net Health News
A new FDA statement advises caution when methotrexate and a proton pump inhibitor are used together - http://t.co/ZJF6aYF6
Lower Incidence Of Cardiovascular Events With Sitagliptin Compared To Sulphonylureas
medicalnewstoday.com — “The incidence of cardiovascular events in patients with type 2 diabetes treated with the DPP-4 inhibitor sitagliptin (Januvia) is significantly lower than in those treated with sulphonylureas, sho” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2011 at 6:05 pm By:
Lower Incidence Of Cardiovascular Events With Sitagliptin Compared To Sulphonylureas http://t.co/tuNUZzS7 #diabetes
Ramipril Improves Walking in Claudicants in RCT : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on November 18, 2011 at 4:52 pm By:
Bob Finn - Medical News Net Health News
Study: ACE inhibitor ramipril boosted walking ability, quality of life in patients with peripheral arterial disease http://t.co/4asOQuBw
Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV
news-medical.net — “Bristol-Myers Squibb Company and Gilead Sciences, Inc. today announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing Bristol-Myers Squibb's protease inhibitor REYATAZ (atazanavir sulfate) and Gilead's cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain HIV medicines to potentially allow for one pill once daily dosing.” View full resource at news-medical.net
Most Recently Shared on October 27, 2011 at 11:54 am By:
Diabetes News: Gilead, Bristol-Myers Squibb to develop and commercialize fixed-dose combination for HIV: Bristol... http://t.co/zQCvgy7l
Juvisync Available for Type 2 Diabetes and High Cholesterol - MPR
empr.com — “Merck announced that Juvisync, a fixed-dose combination product containing the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin and the HMG-CoA reductase inhibitor simvastatin is now available.” View full resource at empr.com
Most Recently Shared on October 26, 2011 at 1:57 pm By:
Juvisync Available for Type 2 #Diabetes and High #Cholesterol http://t.co/xM44w6TT
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study - Nowicki - 2011 - International Journal of Clinical Practi
onlinelibrary.wiley.com — “Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study - Nowicki - 2011 - International Journal of Clinical Practice - Wiley Online Library” View full resource at onlinelibrary.wiley.com
Most Recently Shared on October 11, 2011 at 10:07 pm By:
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in… http://t.co/FVrFij7B viaIJCPRSS
EASD: Positive Results for Two SGLT2 Inhibitors
diabetesincontrol.com — “Diabetes In Control is a free weekly diabetes newsletter dedicated to helping medical professionals in diabetes care better help their diabetes patients.” View full resource at diabetesincontrol.com
Most Recently Shared on September 25, 2011 at 9:50 pm By:
Diabetes Wisdom OW Health and Active Health Library
EASD: Positive Results for Two SGLT2 Inhibitors: The investigational drug ipragliflozin improved glycemic contro... http://t.co/gIRd4WdG
Medical News: EASD: Gliptin Tx Works Long-Term for Glycemic Control - in Meeting Coverage, EASD from MedPage Today
medpagetoday.com — “LISBON -- Long-term treatment of type 2 diabetes with dipeptidyl peptidase-4 (DPP-4) inhibitors for two years appeared to maintain improvement in glycosylated hemoglobin A1c levels, researchers report” View full resource at medpagetoday.com
Most Recently Shared on September 20, 2011 at 4:25 pm By:
Roger D. Jones, PhD PhD, Doctor, Health Executive, and Health Social Media
Medical News: EASD: Gliptin Tx Works Long-Term for Glycemic Control - http://t.co/yClWGEGe from @medpagetoday #health #medicine
Medical News: EASD: 'Gliptin' Diabetes Drugs May Be Heart Savers - in Meeting Coverage, EASD from MedPage Today
medpagetoday.com — “LISBON -- While searching for potential cardiovascular risks among studies involving dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetics, researchers made a surprising discovery -- treatment” View full resource at medpagetoday.com
Most Recently Shared on September 19, 2011 at 9:33 pm By:
Roger D. Jones, PhD PhD, Doctor, Health Executive, and Health Social Media
Medical News: EASD: 'Gliptin' Diabetes Drugs May Be Heart Savers - http://t.co/9D51Tv1U from @medpagetoday #health #medicine
Advertisement
